Furthermore, Ricciuti et al. [72] analyzed clinical outcomes to PD-1/PD-L1 inhibition according to KRAS, STK11, and KEAP1 mutation status in two independent cohorts, at the Dana-Farber Cancer Institute/Massachusetts General Hospital cohort and the Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center cohort, and found that STK11 and KEAP1 mutations confer worse outcomes to IT among patients with KRAS mutant but not KRAS wild type lung adenocarcinoma. This evidence concerns the gene CD274 and lung adenocarcinoma.